dehydroepiandrosterone has been researched along with Osteoporosis in 57 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Young women with anorexia nervosa (AN) have subnormal levels of dehydroepiandrosterone (DHEA) and estrogen that may be mechanistically linked to the bone loss seen in this disease." | 9.10 | Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. ( Becker, KA; Emans, SJ; Feldman, HA; Goodman, E; Gordon, CM; Grace, E; Gundberg, CM; LeBoff, MS; Rosen, CJ, 2002) |
| "Postmenopausal women with sarcopenia were more likely to have lower DHEA levels and higher follistatin levels, and postmenopausal women with osteoporosis were more likely to have lower oxytocin levels." | 8.02 | Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women. ( Chen, M; Cheng, Q; Du, Y; Jiang, X; Li, H; Shi, H; Tang, W; Wu, X; Xu, C; Zhang, X, 2021) |
| "The current study aimed to evaluate the potential role of dehydroepiandrosterone (DHEA) in the protection and intervention of glucocorticoid-induced secondary osteoporosis in female rats." | 7.78 | Role of dehydroepiandrosterone in management of glucocorticoid-induced secondary osteoporosis in female rats. ( Ahmed, HH; Eskander, EF; Morcos, NY; Seoudi, DM; Shalby, AB, 2012) |
| " The objective of the following study was to induce osteoporosis in female rats by ovariectomy, followed by treatment with sustained delivery of Diosgenin (DG), dehydroepiandrosterone (DHEA), or estrogen (E) after clinical signs of osteoporosis." | 7.71 | The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. ( Benghuzzi, H; Cason, Z; Higdon, K; Hughes, J; Puckett, A; Scott, A; Tsao, A; Tucci, M, 2001) |
| "Dehydroepiandrosterone (DHEA) levels decline dramatically with age, concurrent with the onset of osteoporosis, suggesting a role for DHEA supplementation in preventing age-related bone loss." | 5.13 | Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. ( Bergstrom, J; Bettencourt, R; Kritz-Silverstein, D; Laughlin, GA; von Mühlen, D, 2008) |
| "Young women with anorexia nervosa (AN) have subnormal levels of dehydroepiandrosterone (DHEA) and estrogen that may be mechanistically linked to the bone loss seen in this disease." | 5.10 | Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. ( Becker, KA; Emans, SJ; Feldman, HA; Goodman, E; Gordon, CM; Grace, E; Gundberg, CM; LeBoff, MS; Rosen, CJ, 2002) |
| "Dehydroepiandrosterone(DHEA), an adrenal androgen, has attracted much attention as an anti-aging hormone as well as a marker for senescence because of its unique change along with aging." | 4.93 | [Dehydroepiandrosterone(DHEA)and bone metabolism]. ( Ohnaka, K, 2016) |
| "The hypothalamic-pituitary-adrenal axis activity in the aging people is characterised by an unexplained reduction of dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) secretion while ACTH and cortisol production remains relatively unchanged." | 4.84 | [Adrenopause]. ( Krysiak, R; Okopień, B; Szkróbka, W, 2008) |
| "Postmenopausal women with sarcopenia were more likely to have lower DHEA levels and higher follistatin levels, and postmenopausal women with osteoporosis were more likely to have lower oxytocin levels." | 4.02 | Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women. ( Chen, M; Cheng, Q; Du, Y; Jiang, X; Li, H; Shi, H; Tang, W; Wu, X; Xu, C; Zhang, X, 2021) |
| "The current study aimed to evaluate the potential role of dehydroepiandrosterone (DHEA) in the protection and intervention of glucocorticoid-induced secondary osteoporosis in female rats." | 3.78 | Role of dehydroepiandrosterone in management of glucocorticoid-induced secondary osteoporosis in female rats. ( Ahmed, HH; Eskander, EF; Morcos, NY; Seoudi, DM; Shalby, AB, 2012) |
| " The objective of the following study was to induce osteoporosis in female rats by ovariectomy, followed by treatment with sustained delivery of Diosgenin (DG), dehydroepiandrosterone (DHEA), or estrogen (E) after clinical signs of osteoporosis." | 3.71 | The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. ( Benghuzzi, H; Cason, Z; Higdon, K; Hughes, J; Puckett, A; Scott, A; Tsao, A; Tucci, M, 2001) |
| " This loss, combined with the low plasma concentrations of androstenedione, dehydroepiandrosterone, and testosterone (and low concentrations of oestrone of adrenal origin), indicates that adrenal androgens may be essential for the maintenance of bone mass in postmenopausal women with Addison's disease." | 3.67 | Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. ( Crabbé, J; Devogelaer, JP; Nagant de Deuxchaisnes, C, 1987) |
| "To investigate the effects of dehydroepiandrosterone (DHEA) combined with exercise on bone mass, strength, and physical function in older, frail women." | 2.75 | Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. ( Boxer, RS; Brindisi, J; Burleson, JA; Feinn, R; Kenny, AM; Kleppinger, A, 2010) |
| "Dehydroepiandrosterone (DHEA) is a metabolic intermediate in the biosynthesis of estrogens and androgens with a past clouded in controversy and bold claims." | 2.66 | DHEA in bone: the role in osteoporosis and fracture healing. ( Anil, U; Buchalter, DB; Kirby, DJ; Leucht, P, 2020) |
| "Dehydroepiandrosterone (DHEA) is a multifunctional steroid with a broad range of biological effects in humans and animals." | 2.48 | Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports. ( El Kihel, L, 2012) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of prasterone are discussed." | 2.43 | Prasterone. ( Kocis, P, 2006) |
| " Therefore, the deleterious side-effects of chronic administration of GC emerges from both their direct catabolic activity and the suppression of DHEA production." | 2.40 | Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? ( Cutolo, M; Robinzon, B, 1999) |
| " In conclusion, the steroid substitution in Addison's disease requires individually tailored dosage and adequate monitoring." | 1.37 | [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency]. ( Fichna, M; Gryczyńska, M; Sowińska, A; Sowiński, J, 2011) |
| "0052), which was significantly correlated with steroid dosage (r = -0." | 1.31 | Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. ( Bhargava, N; Cheung, J; Fogelman, I; Hampson, G; Seed, PT; Vaja, S, 2002) |
| "Measurements made in patients with Klinefelter's syndrome were compared to those obtained in age-matched normal male volunteers." | 1.28 | Osteoporosis and Klinefelter's syndrome. ( Horowitz, M; Morris, HA; Need, AG; Nordin, BE; O'Loughlin, PD; Wishart, JM, 1992) |
| " Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids." | 1.27 | Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. ( Champion, GD; Eisman, JA; Pocock, NA; Sambrook, PN, 1988) |
| "The severity of the osteoporosis is directly related to the severity of the calcium malabsorption." | 1.27 | The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. ( Bridges, A; Deam, S; Horowitz, M; Morris, HA; Need, AG; Nordin, BE; Philcox, JC; Robertson, A; Seamark, RF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (31.58) | 18.7374 |
| 1990's | 6 (10.53) | 18.2507 |
| 2000's | 20 (35.09) | 29.6817 |
| 2010's | 10 (17.54) | 24.3611 |
| 2020's | 3 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Y | 1 |
| Xu, C | 1 |
| Shi, H | 1 |
| Jiang, X | 1 |
| Tang, W | 1 |
| Wu, X | 1 |
| Chen, M | 1 |
| Li, H | 1 |
| Zhang, X | 1 |
| Cheng, Q | 1 |
| Kirby, DJ | 1 |
| Buchalter, DB | 1 |
| Anil, U | 1 |
| Leucht, P | 1 |
| Huang, K | 1 |
| Cai, HL | 1 |
| Bao, JP | 1 |
| Wu, LD | 1 |
| Ohlsson, C | 2 |
| Nethander, M | 2 |
| Karlsson, MK | 2 |
| Rosengren, BE | 2 |
| Ribom, E | 1 |
| Mellström, D | 2 |
| Vandenput, L | 2 |
| Zhou, S | 1 |
| Glowacki, J | 1 |
| Ohnaka, K | 1 |
| Kindmark, A | 1 |
| Ljunggren, Ö | 1 |
| Lorentzon, M | 1 |
| Sánchez-Guerrero, J | 1 |
| Fragoso-Loyo, HE | 1 |
| Neuwelt, CM | 1 |
| Wallace, DJ | 1 |
| Ginzler, EM | 1 |
| Sherrer, YR | 1 |
| McIlwain, HH | 1 |
| Freeman, PG | 1 |
| Aranow, C | 1 |
| Petri, MA | 1 |
| Deodhar, AA | 1 |
| Blanton, E | 1 |
| Manzi, S | 1 |
| Kavanaugh, A | 1 |
| Lisse, JR | 1 |
| Ramsey-Goldman, R | 1 |
| McKay, JD | 1 |
| Kivitz, AJ | 1 |
| Mease, PJ | 1 |
| Winkler, AE | 1 |
| Kahl, LE | 1 |
| Lee, AH | 1 |
| Furie, RA | 1 |
| Strand, CV | 1 |
| Lou, L | 1 |
| Ahmed, M | 1 |
| Quarles, B | 1 |
| Schwartz, KE | 1 |
| Szkróbka, W | 1 |
| Krysiak, R | 1 |
| Okopień, B | 1 |
| Herman, WA | 1 |
| Seńko, A | 1 |
| Korczowska, I | 1 |
| Łacka, K | 1 |
| Marder, W | 1 |
| Somers, EC | 1 |
| Kaplan, MJ | 1 |
| Anderson, MR | 1 |
| Lewis, EE | 1 |
| McCune, WJ | 1 |
| Kenny, AM | 1 |
| Boxer, RS | 1 |
| Kleppinger, A | 1 |
| Brindisi, J | 1 |
| Feinn, R | 1 |
| Burleson, JA | 1 |
| Ahmed, HH | 1 |
| Morcos, NY | 1 |
| Eskander, EF | 1 |
| Seoudi, DM | 1 |
| Shalby, AB | 1 |
| Fichna, M | 1 |
| Gryczyńska, M | 1 |
| Sowińska, A | 1 |
| Sowiński, J | 1 |
| El Kihel, L | 1 |
| Papierska, L | 1 |
| Rabijewski, M | 1 |
| Kasperlik-Załuska, A | 1 |
| Zgliczyński, W | 1 |
| Burd, ID | 1 |
| Bachmann, GA | 1 |
| Hampson, G | 1 |
| Bhargava, N | 1 |
| Cheung, J | 1 |
| Vaja, S | 1 |
| Seed, PT | 1 |
| Fogelman, I | 1 |
| Gordon, CM | 1 |
| Grace, E | 1 |
| Emans, SJ | 1 |
| Feldman, HA | 1 |
| Goodman, E | 1 |
| Becker, KA | 1 |
| Rosen, CJ | 1 |
| Gundberg, CM | 1 |
| LeBoff, MS | 1 |
| Oncken, C | 1 |
| Prestwood, K | 1 |
| Cooney, JL | 1 |
| Unson, C | 1 |
| Fall, P | 1 |
| Kulldorff, M | 1 |
| Raisz, LG | 1 |
| ZARA, M | 1 |
| LUMBROSO, A | 1 |
| INTINI, L | 1 |
| Yamada, Y | 1 |
| Sekihara, H | 1 |
| Villareal, DT | 1 |
| Kocis, P | 1 |
| McCormick, RK | 1 |
| von Mühlen, D | 1 |
| Laughlin, GA | 1 |
| Kritz-Silverstein, D | 2 |
| Bergstrom, J | 1 |
| Bettencourt, R | 1 |
| Brückel, J | 1 |
| Davidson, BJ | 1 |
| Riggs, BL | 1 |
| Wahner, HW | 1 |
| Judd, HL | 1 |
| Brody, S | 1 |
| Carlström, K | 1 |
| Lagrelius, A | 1 |
| Lunell, NO | 1 |
| Rosenborg, L | 1 |
| Crilly, RG | 2 |
| Francis, RM | 1 |
| Nordin, BE | 4 |
| Nawata, H | 2 |
| Tanaka, S | 3 |
| Takayanagi, R | 2 |
| Sakai, Y | 1 |
| Yanase, T | 1 |
| Ikuyama, S | 1 |
| Haji, M | 2 |
| Barrett-Connor, E | 1 |
| Edelstein, SL | 1 |
| Kuritzky, L | 1 |
| Robinzon, B | 1 |
| Cutolo, M | 1 |
| Kwak, CS | 1 |
| Kang, CM | 1 |
| Kang, HS | 1 |
| Song, KY | 1 |
| Lee, MS | 1 |
| Seong, SC | 1 |
| Park, SC | 1 |
| Kamel, HK | 1 |
| Perry, HM | 1 |
| Morley, JE | 1 |
| Scott, A | 2 |
| Higdon, K | 2 |
| Tucci, M | 2 |
| Benghuzzi, H | 2 |
| Puckett, A | 2 |
| Tsao, A | 2 |
| Cason, Z | 2 |
| Hughes, J | 2 |
| Rigaud, AS | 1 |
| Pellerin, J | 1 |
| Manolagas, SC | 1 |
| Anderson, DC | 1 |
| Lindsay, R | 1 |
| Breckwoldt, M | 1 |
| Holló, I | 2 |
| Szalay, F | 1 |
| Steczek, K | 1 |
| Szücs, J | 2 |
| Marshall, DH | 1 |
| Horowitz, M | 2 |
| Wishart, JM | 1 |
| O'Loughlin, PD | 1 |
| Morris, HA | 2 |
| Need, AG | 2 |
| Fabbri, G | 1 |
| Petraglia, F | 1 |
| Segre, A | 1 |
| Maietta-Latessa, A | 1 |
| Galassi, MC | 1 |
| Cellini, M | 1 |
| Sardelli, S | 1 |
| Massolo, F | 1 |
| Genazzani, A | 1 |
| Genazzani, AR | 1 |
| Taelman, P | 1 |
| Kaufman, JM | 1 |
| Janssens, X | 1 |
| Vermeulen, A | 1 |
| Devogelaer, JP | 1 |
| Crabbé, J | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Ribot, C | 1 |
| Tremollieres, F | 1 |
| Pouilles, JM | 1 |
| Bonneu, M | 1 |
| Germain, F | 1 |
| Louvet, JP | 1 |
| Sambrook, PN | 1 |
| Eisman, JA | 1 |
| Champion, GD | 1 |
| Pocock, NA | 1 |
| Robertson, A | 1 |
| Seamark, RF | 1 |
| Bridges, A | 1 |
| Philcox, JC | 1 |
| Deam, S | 1 |
| Nishida, E | 1 |
| Fehér, T | 1 |
| Morii, H | 1 |
| Tanae, A | 1 |
| Ibayashi, H | 1 |
| Nakao, K | 1 |
| Staub, JJ | 1 |
| Philbert, M | 1 |
| Luton, JP | 1 |
| Bricaire, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids[NCT00053560] | Phase 3 | 155 participants | Interventional | 2002-12-31 | Active, not recruiting | ||
| A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids[NCT00082511] | Phase 3 | 114 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Effects of DHEA/Exercise on Bone, Muscle and Balance[NCT00664053] | Phase 4 | 99 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| DHEA+Exercise-Effect on Sarcopenia and Osteopenia of Aging[NCT00205686] | Phase 3 | 64 participants | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for dehydroepiandrosterone and Osteoporosis
| Article | Year |
|---|---|
DHEA in bone: the role in osteoporosis and fracture healing.
Topics: Dehydroepiandrosterone; Fracture Healing; Humans; Osteoporosis; Testosterone | 2020 |
Dehydroepiandrosterone and age-related musculoskeletal diseases: Connections and therapeutic implications.
Topics: Aged; Aging; Dehydroepiandrosterone; Humans; Musculoskeletal Diseases; Osteoporosis; Sarcopenia | 2020 |
[Dehydroepiandrosterone(DHEA)and bone metabolism].
Topics: Aging; Bone and Bones; Bone Density; Dehydroepiandrosterone; Hormone Replacement Therapy; Humans; Os | 2016 |
[Adrenopause].
Topics: Adolescent; Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aged; Aging; Androgens; Ather | 2008 |
Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports.
Topics: Androsterone; Animals; Brain; Cardiovascular Diseases; Dehydroepiandrosterone; Female; Humans; Hydro | 2012 |
Androgen replacement in menopause.
Topics: Androgens; Androstenedione; Bone Density; Dehydroepiandrosterone; Female; Hormone Replacement Therap | 2001 |
[DHEA: hormone as antiaging remedies].
Topics: Aged; Aging; Animals; Anti-Inflammatory Agents; Brain; Dehydroepiandrosterone; Dementia; Female; Hum | 2003 |
Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy?
Topics: Adjuvants, Immunologic; Bone Density; Dehydroepiandrosterone; Humans; Osteoporosis | 2002 |
Prasterone.
Topics: Adjuvants, Immunologic; Adult; Biological Availability; Bone Density; Dehydroepiandrosterone; Drug A | 2006 |
Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility.
Topics: Absorptiometry, Photon; Acidosis; Biomarkers; Bone Density; Bone Remodeling; C-Reactive Protein; Cal | 2007 |
[Replacement and supplementation of DHEA--is it a wellness hormone?].
Topics: Addison Disease; Adjuvants, Immunologic; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 an | 2005 |
Steroid hormones, ageing and bone.
Topics: Adult; Aged; Aging; Androstenedione; Bone and Bones; Calcium; Castration; Dehydroepiandrosterone; Es | 1981 |
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
Topics: Aged; Androstenedione; Animals; Aromatase; Base Sequence; Bone and Bones; Bone Density; Calcitriol; | 1995 |
DHEA: science or wishful thinking?
Topics: Adult; Aged; Aging; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Obesity; Osteoporosis | 1998 |
Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?
Topics: Adjuvants, Immunologic; Atrophy; Autoimmunity; Dehydroepiandrosterone; Diabetes Mellitus; Female; Gl | 1999 |
Hormone replacement therapy and fractures in older adults.
Topics: Age Distribution; Age Factors; Aged; Chemistry, Pharmaceutical; Dehydroepiandrosterone; Estrogen Rep | 2001 |
[Neuropsychic effects of dehydroepiandrosterone].
Topics: Affect; Aging; Animals; Attention; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandros | 2001 |
[Androgen in the treatment of osteoporosis ].
Topics: Androgens; Animals; Aromatase; Bone Density; Dehydroepiandrosterone; Estrogens; Fractures, Stress; H | 2002 |
[Clinical findings and laboratory diagnosis in Cushing's syndrome].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic | 1968 |
8 trials available for dehydroepiandrosterone and Osteoporosis
| Article | Year |
|---|---|
Low Serum DHEAS Predicts Increased Fracture Risk in Older Men: The MrOS Sweden Study.
Topics: Aged; Aged, 80 and over; Aging; Dehydroepiandrosterone; Fractures, Bone; Humans; Incidence; Male; Os | 2017 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study.
Topics: Adjuvants, Immunologic; Adult; Atherosclerosis; Bone Density; Cholesterol, HDL; Cross-Over Studies; | 2010 |
Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women.
Topics: Adjuvants, Immunologic; Administration, Oral; Aged; Bone Density; Dehydroepiandrosterone; Dose-Respo | 2010 |
Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women.
Topics: Aged; Bone Density; Dehydroepiandrosterone; Female; Glucocorticoids; Humans; Insulin-Like Growth Fac | 2012 |
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial.
Topics: Adipose Tissue; Adolescent; Adult; Alkaline Phosphatase; Anorexia Nervosa; Body Composition; Body Im | 2002 |
Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women.
Topics: Dehydroepiandrosterone; Estradiol; Estrogen Replacement Therapy; Estrone; Female; Humans; Middle Age | 2002 |
Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial.
Topics: Aged; Aged, 80 and over; Biomarkers; Body Composition; Bone Density; Bone Density Conservation Agent | 2008 |
30 other studies available for dehydroepiandrosterone and Osteoporosis
| Article | Year |
|---|---|
Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Dehydroepiandrosterone; Female; Follistatin; Human | 2021 |
Serum DHEA and Its Sulfate Are Associated With Incident Fall Risk in Older Men: The MrOS Sweden Study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; F | 2018 |
Dehydroepiandrosterone and Bone.
Topics: Animals; Bone Density; Dehydroepiandrosterone; Gene Expression Regulation, Developmental; Humans; In | 2018 |
[Could serum DHEA and DHEAS levels be good risk predictors of metabolic syndrome and osteoporosis in the population of ageing men?].
Topics: Adult; Aged; Aged, 80 and over; Aging; Comorbidity; Dehydroepiandrosterone; Dementia; Humans; Hypert | 2009 |
Role of dehydroepiandrosterone in management of glucocorticoid-induced secondary osteoporosis in female rats.
Topics: Animals; Bone and Bones; Dehydroepiandrosterone; Female; Glucocorticoids; Osteoporosis; Prednisolone | 2012 |
[Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
Topics: Addison Disease; Adolescent; Adult; Aged; Dehydroepiandrosterone; Drug Therapy, Combination; Female; | 2011 |
Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis.
Topics: Adult; Aged; Bone Density; Calcium; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Estrad | 2002 |
[Therapeutic study of a new anabolic drug: nor-androstenolone phenylpropionate].
Topics: Body Weight; Body Weights and Measures; Bone and Bones; Dehydroepiandrosterone; Neoplasms; Osteoporo | 1960 |
[USE OF AN ANABOLIZING AGENT (1-METHYL-DELTA-ANDROSTENOLONE) AS A PREVENTIVE OF OSTEOPOROSIS IN PATIENTS SUBJECTED TO PLASTER CAST IMMOBILIZATION].
Topics: Anabolic Agents; Casts, Surgical; Dehydroepiandrosterone; Humans; Immobilization; Osteoporosis; Ster | 1965 |
Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures.
Topics: Androgens; Androstenedione; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1983 |
Adrenal steroids, bone mineral content and endometrial pathology in postmenopausal women.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Bone and Bones; Dehydroepiandrosterone; Dehydr | 1981 |
A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Antihypertensive Agents; Bone Density; California; Dehydr | 1993 |
Dehydroepiandrosterone-dependent induction of peroxisomal proliferation can be reduced by aspartyl esterification without attenuation of inhibitory bone loss in ovariectomy animal model.
Topics: Acyl-CoA Dehydrogenase; Adjuvants, Immunologic; Animals; Aspartic Acid; Biomarkers; Calcium; Cholest | 2000 |
The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems.
Topics: Animals; Bone Resorption; Calcium Phosphates; Dehydroepiandrosterone; Diosgenin; Disease Progression | 2001 |
The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model.
Topics: Animals; Calcium Phosphates; Capsules; Ceramics; Dehydroepiandrosterone; Diosgenin; Drug Delivery Sy | 2001 |
[DHEA, osteoporosis, nuclear receptor and aging].
Topics: Administration, Oral; Aged; Aging; Bone and Bones; Dehydroepiandrosterone; Female; Humans; Male; Mid | 2001 |
Adrenal steroids and the development of osteoporosis in oophorectomised women.
Topics: 17-Ketosteroids; Adult; Androgens; Androstenediols; Androstenedione; Castration; Dehydroepiandroster | 1979 |
[Diseases in the climacteric, with poor or without any organic findings].
Topics: Cardiovascular Diseases; Climacteric; Dehydroepiandrosterone; Estradiol; Estrogens; Female; Humans; | 1975 |
Effect of intravenous calcium load on the serum calcium level in postmenopausal osteoporosis (a study of the pathogenesis, and diagnostic use of the test).
Topics: Calcium; Decanoates; Dehydroepiandrosterone; Female; Humans; Menopause; Nandrolone; Osteoporosis | 1978 |
Metabolic effects of corticosteroid therapy in post-menopausal women.
Topics: Androstenedione; Bone and Bones; Calcium; Creatinine; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1979 |
Osteoporosis and Klinefelter's syndrome.
Topics: Adult; Aged; Body Composition; Bone Density; Creatinine; Dehydroepiandrosterone; Humans; Hydroxyprol | 1992 |
Reduced spinal bone density in young women with amenorrhoea.
Topics: Adolescent; Adult; Amenorrhea; Bone Density; Dehydroepiandrosterone; Estradiol; Female; Humans; Hydr | 1991 |
Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause.
Topics: Age Factors; Aged; Aged, 80 and over; Bone and Bones; Bone Resorption; Dehydroepiandrosterone; Femal | 1989 |
Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass.
Topics: Addison Disease; Adult; Aged; Androgens; Androstenedione; Bone and Bones; Dehydroepiandrosterone; Es | 1987 |
Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women.
Topics: Aged; Bone and Bones; Calcium; Calcium-Binding Proteins; Dehydroepiandrosterone; Estradiol; Female; | 1987 |
Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Femal | 1988 |
The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Calcium; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Intestinal Ab | 1985 |
[Effect of dehydroepiandrosterone and cortisol on the bones of bilaterally adrenalectomized female rats].
Topics: Adrenalectomy; Animals; Bone and Bones; Dehydroepiandrosterone; Desoxycorticosterone; Female; Femur; | 1966 |
Serum dehydroepiandrosterone, androsterone and cortisol level in primary postmenopausal and other type osteoporosis.
Topics: Adrenal Cortex Hormones; Androsterone; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Menop | 1970 |
Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcitonin; Calcium; Child, Presc | 1971 |